Last Updated : August 18, 2023
Details
Generic Name:
cannabidiol
Project Status:
Pending
Therapeutic Area:
Seizures associated with Tuberous Sclerosis Complex (TSC)
Manufacturer:
Jazz Pharmaceuticals Canada, Inc.
Call for patient/clinician input open:
Brand Name:
Epidiolex
Project Line:
Reimbursement Review
Project Number:
SR0798-000
Call for patient/clinician input closed:
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
Jazz Pharmaceuticals Canada Inc. are requesting CADTH review this for: the adjunctive therapy with other anti-seizure medications for the treatment of seizures associated with TSC in patients two years of age and older.
Submission Type:
Initial
Fee Schedule:
Pending
Indications:
Epidiolex is indicated as adjunctive therapy with other anti-seizure medications for the treatment of seizures associated with Tuberous Sclerosis Complex (TSC) in patients 2 years of age and older.
Anticipated Date:
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.
Last Updated : August 18, 2023